Tesamorelin + Ipamorelin

About Tesamorelin + Ipamorelin

This blend pairs Tesamorelin (10 mg), a stabilized GHRH (growth hormone–releasing hormone) analog that is FDA-approved for the reduction of visceral adipose tissue in HIV-associated lipodystrophy, with Ipamorelin (3 mg), a highly selective growth hormone secretagogue (ghrelin-receptor agonist) that stimulates GH release without meaningfully raising cortisol or prolactin. The combination is researched for amplified, naturally pulsatile GH output — targeting visceral fat reduction, body recomposition, and recovery — with the two compounds acting on complementary receptors (GHRH-R and GHS-R).

Dosing & Reconstitution Guide

— Tesamorelin 10 mg + Ipamorelin 3 mg Blend Vial —

Reconstitute: Add 0.5 mL of 0.6% acetic acid solution first and swirl until fully dissolved, then add 2.5 mL bacteriostatic water. The acetic acid step is mandatory to prevent gelling of the product. Hospira-brand BAC water is preferred — it maintains a known, consistent pH (pH swings from other brands can cause peptides to clump or denature).
Administration: Subcutaneous injection.
Timing: Dose at night, at least 90 minutes after your last meal.
Storage: Refrigerate the lyophilized vial before reconstitution; allow everything to reach room temperature before mixing. After reconstitution, store at room temperature — do NOT refrigerate (refrigeration promotes gelling). Use within 2 weeks of reconstitution.

Schedule: 5 consecutive dosing days followed by 2 rest days, each week.
Cycle Length: 12–16 week cycle, followed by a 4–8 week washout period. Shorter cycles will not yield tangible results — do not start this blend intending to “try it out” for 3–4 weeks.
Goal: Visceral fat reduction, body recomposition, and GH-axis support.

Standard Protocol

Phase	Dose	Syringe (U-100)
Weeks 1–6	23 units once daily at bedtime, 5 consecutive days/week	23 units (0.23 mL)
Weeks 7–12+	Remain at 23 units/day, 5 days/week for the rest of the cycle	23 units (0.23 mL)

Maximum Protocol

Phase	Dose	Syringe (U-100)
Weeks 1–6	23 units once daily at bedtime, 5 consecutive days/week	23 units (0.23 mL)
Weeks 7–12+	Increase to 46 units/day, 5 consecutive days/week for the rest of the cycle	46 units (0.46 mL)

Benefits (Reported in Research)

• Reduction of visceral (abdominal) adipose tissue — Tesamorelin’s primary studied effect.
• Increased pulsatile growth hormone and IGF-1 output.
• Selective GH release without significant cortisol or prolactin elevation (Ipamorelin).
• Support for lean mass retention and body recomposition.
• Improved recovery and sleep-cycle GH pulse when dosed at bedtime.

Side Effects

While side effects are not common, you may experience:

• Irritation, redness, or swelling at the injection site
• Water retention or joint aches (typical of elevated GH activity)
• Headache
• Flushing or warmth after injection
• Numbness/tingling (paresthesia)

Contraindications

• Do not use when pregnant or nursing.
• Do not use with active malignancy — GH-axis stimulation is contraindicated with active cancer.
• Use caution with diabetes or impaired glucose tolerance — GH elevation can affect insulin sensitivity.
• Do not use with disrupted hypothalamic-pituitary function (e.g., pituitary tumor, hypophysectomy, head irradiation).

Stacking Suggestions

This blend is itself a GHRH + GHRP stack. Common research pairings include:

• CJC-1295 No DAC – Additional GHRH-receptor stimulation (see the Tesamorelin + Ipamorelin + CJC No DAC blend)
• AOD-9604 – For additional fat-metabolism support
• BPC-157 / TB-500 – Tissue repair alongside recomposition work

Research Sources

PubMed-linked citations for verification. Many studies are animal/in-vitro.

1. Metabolic effects of a growth hormone-releasing factor in patients with HIV (tesamorelin). N Engl J Med. 2007;357(23):2359-70. PMID: 18057338
2. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10):e0140358. PMID: 26457580
3. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822